Surya Singh, MD, discussed dynamics that affect biosimilar uptake on the medical benefits side and how that differs from the pharmacy benefits side at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
Surya Singh, MD, is the president of Singh Healthcare Advisors
Transcript:
What are some of the dynamics that affect biosimilar uptake on the medical benefits side versus the pharmacy benefits side?
On the pharmacy benefit side, just to start there, the formulary concept and preferred drug concepts are critical to user uptake. So, getting that contract to become the preferred product, which in today's market is really around achieving the lowest net cost, is really critical. And that's done on a really large scale through a few entities, [which] do a lot of the procurement on the pharmacy benefit side; whereas, on the medical benefits side, individual health systems, academic medical centers, for instance, and then large multidisciplinary practices or specialty specific practices do their own procurement. So, the splintering of the market is much greater, and providers have to think about what would be the best, really, largely from an economic perspective, so [what would be the] lowest cost for them to inventory and then use across all of their patients and be able to [bill] for and receive reimbursement for across all of their patients. If it's a pure play, and it's going through either benefit, then the adoption issues become more clear, given that kind of framework. What becomes even more complicated is when there's both pharmacy benefit coverage and adjudication and medical benefit coverage and adjudication. So, you have both to contend with.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.